Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nandrolone for muscle recovery after prolonged intensive care
ACTRN12623000729628Phase 3Recruiting
- Sponsor
- Sir Charles Gairdner Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in critical illness neuromuscular disease (CINM) and acute quadriplegic myopathy (CIM) comparing Nandrolone with Placebo (2 arms). Primary endpoints: Time to walking with one-person assistance and Days out of hospital to day 90. Started Jul 2023; status: recruiting.
02
Drugs
nandrolone
03
Conditions
critical illness neuromuscular disease (CINM)acute quadriplegic myopathy (CIM)
Beyond the preview
Go deeper on ACTRN12623000729628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000729628.